Evotec and Pfizer Unite For Revolutionary Drug Innovations In French Labs

Evotec SE has announced a new multi-year master research collaboration, option, and license agreement with Pfizer. This partnership will initially focus on early discovery research targeting metabolic and infectious diseases. The research activities will take place at Evotec’s facilities in France, including the advanced research site Campus Curie in Toulouse. This location boasts cutting-edge capabilities in high throughput screening, in vitro and in vivo biology, proteomics, and metabolomics. Pfizer will provide research support funding to Evotec, with potential milestones and royalties tied to the success of the programs.

Dr Matthias Evers, Chief Business Officer at Evotec, said, “We are honoured to collaborate with Pfizer to research potential new first-in-class therapeutic approaches. France has established a thriving biopharmaceutical ecosystem to which Evotec also contributes with its strong presence with more than 1,000 employees at our French sites, building a strong pipeline of medicines that matter. Focussing on diseases with severe unmet medical need and highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D activities.”

Dr Luca Mollo, Vice President and Medical Lead France at Pfizer, made a remark “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. France has developed a strong biopharmaceutical ecosystem, which is why we’re thrilled to collaborate with Evotec to build on our shared commitment to advancing scientific discovery for diseases with unmet need.”